IDEXX Laboratories, Inc. (IDXX) recently expanded its Fecal Dx antigen testing platform with the addition of Cystoisospora —  a common intestinal parasite that is the source of diarrhea, weight loss and dehydration — primarily in young dogs and cats. Fecal Dx antigen testing with Cystoisospora will be offered at IDEXX Reference Laboratories in March in North America and globally in third-quarter 2024.The recent development will bolster IDEXX’s Livestock, Poultry and Dairy (LPD) business.More on Fecal Antige ...

Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infectionsWESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlie ...

AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology casesThe global launch of the IDEXX inVue Dx analyzer will begin in late 2024WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes ...

Call Start: 8:30 January 1, 0000 9:27 AM ET IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Erin Wright - Morgan Stanley Chris Schott - JP Morgan John Block - Stifel Brandon Vasquez - William Blair Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Dela ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2023 Earnings Conference Call August 1, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Michael Ryskin - Bank of America Ryan Daniels - William Blair John Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Executive Vice President, Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Christopher Schott - JPMorgan Jonathan Block - Stifel Michael Ryskin - Bank of America Jack Senft - William Blair Erin Wright - Morgan Stanley David Westenberg - Piper Sandl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-0393723 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...